Adrenomedullin and tumour microenvironment

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Larráyoz, Ignacio M ^a   Martínez Herrero, Sonia ^a   García Sanmartín, Josune ^a   Ochoa Callejero, Laura ^a   Martínez, Alfredo ^a  

^a CENTER FOR BIOMEDICAL RESEARCH OF LA RIOJA CIBIR   (Spain)

Author keywords

Adrenomedullin; Angiogenesis; CLR; PAMP; RAMP; Tumour growth; Tumour microenvironment; Xenograft

Indexed keywords

ADRENOMEDULLIN; ADRENOMEDULLIN INHIBITOR; ADRENOMEDULLIN RECEPTOR ANTAGONIST; ETOPOSIDE; GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NEUTRALIZING ANTIBODY; NEW DRUG; PEPTIDE; PROTEIN INHIBITOR; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; ADRENOMEDULLIN RECEPTOR;

ANGIOGENESIS; APOPTOSIS; AUTOCRINE EFFECT; BREAST CANCER; CANCER PATIENT; CANCER PROGNOSIS; CELL DEATH; CELL MOTILITY; CELL SURVIVAL; DRUG DEVELOPMENT; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; HYPOXIA; IMMUNE SYSTEM; IMMUNOSURVEILLANCE; MACROPHAGE; MAST CELL; METASTASIS; NONHUMAN; PANCREAS CANCER; PARACRINE SIGNALING; PROTEIN SECRETION; PROTEIN SYNTHESIS; REVIEW; SKIN CANCER; SMOOTH MUSCLE FIBER; STROMA CELL; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; VASCULAR SMOOTH MUSCLE; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ADRENOMEDULLIN; HUMANS; RECEPTORS, ADRENOMEDULLIN; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84924766414     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-014-0339-2     Document Type: Review

References (195)

1. Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, Eto T: Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993, 192:553-560.
2. Hinson JP, Kapas S, Smith DM: Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev 2000, 21:138-167.
3. Zudaire E, Portal-Nunez S, Cuttitta F: The central role of adrenomedullin in host defense. J Leukoc Biol 2006, 80:237-244.
4. Lopez J, Martinez A: Cell and molecular biology of the multifunctional peptide, adrenomedullin. Int Rev Cytol 2002, 221:1-92.
5. Beltowski J, Jamroz A: Adrenomedullin-what do we know 10 years since its discovery? Pol J Pharmacol 2004, 56:5-27.
6. Takei Y, Inoue K, Ogoshi M, Kawahara T, Bannai H, Miyano S: Identification of novel adrenomedullin in mammals: a potent cardiovascular and renal regulator. FEBS Lett 2004, 556:53-58.
7. Roh J, Chang CL, Bhalla A, Klein C, Hsu SY: Intermedin is a calcitonin/calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like receptor/receptor activity-modifying protein receptor complexes. J Biol Chem 2004, 279:7264-7274.
8. Perez-Castells J, Martin-Santamaria S, Nieto L, Ramos A, Martinez A, de Pascual-Teresa B, Jimenez-Barbero J: Structure of micelle-bound adrenomedullin: a first step toward the analysis of its interactions with receptors and small molecules. Biopolymers 2012, 97:45-53.
9. Garayoa M, Martinez A, Lee S, Pio R, An WG, Neckers L, Trepel J, Montuenga LM, Ryan H, Johnson R, Gassmann M, Cuttitta F: Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in human tumor cell lines during oxygen deprivation: a possible promotion mechanism of carcinogenesis. Mol Endocrinol 2000, 14:848-862.
10. Pio R, Elsassr TH, Martinez A, Cuttitta F: Identification, characterization, and physiological actions of factor H as an adrenomedullin binding protein present in human plasma. Microsc Res Tech 2002, 57:23-27.
11. Dupuis J, Caron A, Ruël N: Biodistribution, plasma kinetics and quantification of single-pass pulmonary clearance of adrenomedullin. Clin Sci (Lond) 2005, 109:97-102.
12. Martinez A, Oh HR, Unsworth EJ, Bregonzio C, Saavedra JM, Stetler-Stevenson WG, Cuttitta F: Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator. Biochem J 2004, 383:413-418.
13. Juaneda C, Dumont Y, Chabot JG, Fournier A, Quirion R: Adrenomedullin receptor binding sites in rat brain and peripheral tissues. Eur J Pharmacol 2003, 474:165-174.
14. Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W, Muff R, Fischer JA, Foord SM: International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev 2002, 54:233-246.
15. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, Foord SM: RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 1998, 393:333-339.
16. Qi T, Christopoulos G, Bailey RJ, Christopoulos A, Sexton PM, Hay DL: Identification of N-terminal receptor activity-modifying protein residues important for calcitonin gene-related peptide, adrenomedullin, and amylin receptor function. Mol Pharmacol 2008, 74:1059-1071.
17. Jacob A, Wu R, Wang P: Regulation of RAMP expression in diseases. Adv Exp Med Biol 2012, 744:87-103.
18. Gibbons C, Dackor R, Dunworth W, Fritz-Six K, Caron KM: Receptor activity-modifying proteins: RAMPing up adrenomedullin signaling. Mol Endocrinol 2007, 21:783-796.
19. Nikitenko LL, Leek R, Henderson S, Pillay N, Turley H, Generali D, Gunningham S, Morrin HR, Pellagatti A, Rees MC, Harris AL, Fox SB: The G-protein-coupled receptor CLR is upregulated in an autocrine loop with adrenomedullin in clear cell renal cell carcinoma and associated with poor prognosis. Clin Cancer Res 2013, 19:5740-5748.
20. Shimekake Y, Nagata K, Ohta S, Kambayashi Y, Teraoka H, Kitamura K, Eto T, Kangawa K, Matsuo H: Adrenomedullin stimulates two signal transduction pathways, cAMP accumulation and Ca2+ mobilization, in bovine aortic endothelial cells. J Biol Chem 1995, 270:4412-4417.
21. Szokodi I, Kinnunen P, Tavi P, Weckström M, Tóth M, Ruskoaho H: Evidence for cAMP-independent mechanisms mediating the effects of adrenomedullin, a new inotropic peptide. Circulation 1998, 97:1062-1070.
22. Hippenstiel S, Witzenrath M, Schmeck B, Hocke A, Krisp M, Krüll M, Seybold J, Seeger W, Rascher W, Schütte H, Suttorp N: Adrenomedullin reduces endothelial hyperpermeability. Circ Res 2002, 91:618-625.
23. Kureishi Y, Kobayashi S, Nishimura J, Nakano T, Kanaide H: Adrenomedullin decreases both cytosolic Ca2+ concentration and Ca(2+)-sensitivity in pig coronary arterial smooth muscle. Biochem Biophys Res Commun 1995, 212:572-579.
24. Ikeda U, Kanbe T, Kawahara Y, Yokoyama M, Shimada K: Adrenomedullin augments inducible nitric oxide synthase expression in cytokine-stimulated cardiac myocytes. Circulation 1996, 94:2560-2565.
25. Shimosawa T, Matsui H, Xing G, Itakura K, Ando K, Fujita T: Organ-protective effects of adrenomedullin. Hypertens Res 2003, 26(Suppl):S109-S112.
26. Looi YH, Kane KA, McPhaden AR, Wainwright CL: Adrenomedullin acts via nitric oxide and peroxynitrite to protect against myocardial ischaemia-induced arrhythmias in anaesthetized rats. Br J Pharmacol 2006, 148:599-609.
27. Sata M, Kakoki M, Nagata D, Nishimatsu H, Suzuki E, Aoyagi T, Sugiura S, Kojima H, Nagano T, Kangawa K, Matsuo H, Omata M, Nagai R, Hirata Y: Adrenomedullin and nitric oxide inhibit human endothelial cell apoptosis via a cyclic GMP-independent mechanism. Hypertension 2000, 36:83-88.
28. Mannick JB, Miao XQ, Stamler JS: Nitric oxide inhibits Fas-induced apoptosis. J Biol Chem 1997, 272:24125-24128.
29. Rössig L, Fichtlscherer B, Breitschopf K, Haendeler J, Zeiher AM, Mülsch A, Dimmeler S: Nitric oxide inhibits caspase-3 by S-nitrosation in vivo. J Biol Chem 1999, 274:6823-6826.
30. Sinz EH, Kochanek PM, Dixon CE, Clark RS, Carcillo JA, Schiding JK, Chen M, Wisniewski SR, Carlos TM, Williams D, DeKosky ST, Watkins SC, Marion DW, Billiar TR: Inducible nitric oxide synthase is an endogenous neuroprotectant after traumatic brain injury in rats and mice. J Clin Invest 1999, 104:647-656.
31. Nishimatsu H, Suzuki E, Nagata D, Moriyama N, Satonaka H, Walsh K, Sata M, Kangawa K, Matsuo H, Goto A, Kitamura T, Hirata Y: Adrenomedullin induces endothelium-dependent vasorelaxation via the phosphatidylinositol 3-kinase/Akt-dependent pathway in rat aorta. Circ Res 2001, 89:63-70.
32. Fernandez-Sauze S, Delfino C, Mabrouk K, Dussert C, Chinot O, Martin PM, Grisoli F, Ouafik L, Boudouresque F: Effects of adrenomedullin on endothelial cells in the multistep process of angiogenesis: involvement of CRLR/RAMP2 and CRLR/RAMP3 receptors. Int J Cancer 2004, 108:797-804.
33. Okumura H, Nagaya N, Itoh T, Okano I, Hino J, Mori K, Tsukamoto Y, Ishibashi-Ueda H, Miwa S, Tambara K, Toyokuni S, Yutani C, Kangawa K: Adrenomedullin infusion attenuates myocardial ischemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway. Circulation 2004, 109:242-248.
34. Fritz-Six KL, Dunworth WP, Li M, Caron KM: Adrenomedullin signaling is necessary for murine lymphatic vascular development. J Clin Invest 2008, 118:40-50.
35. Iwasaki H, Eguchi S, Shichiri M, Marumo F, Hirata Y: Adrenomedullin as a novel growth-promoting factor for cultured vascular smooth muscle cells: role of tyrosine kinase-mediated mitogen-activated protein kinase activation. Endocrinology 1998, 139:3432-3441.
36. Iwasaki H, Shichiri M, Marumo F, Hirata Y: Adrenomedullin stimulates proline-rich tyrosine kinase 2 in vascular smooth muscle cells. Endocrinology 2001, 142:564-572.
37. Parameswaran N, Nambi P, Brooks DP, Spielman WS: Regulation of glomerular mesangial cell proliferation in culture by adrenomedullin. Eur J Pharmacol 1999, 372:85-95.
38. Oehler MK, Norbury C, Hague S, Rees MC, Bicknell R: Adrenomedullin inhibits hypoxic cell death by upregulation of Bcl-2 in endometrial cancer cells: a possible promotion mechanism for tumour growth. Oncogene 2001, 20:2937-2945.
39. Shindo T, Kurihara Y, Nishimatsu H, Moriyama N, Kakoki M, Wang Y, Imai Y, Ebihara A, Kuwaki T, Ju KH, Minamino N, Kangawa K, Ishikawa T, Fukuda M, Akimoto Y, Kawakami H, Imai T, Morita H, Yazaki Y, Nagai R, Hirata Y, Kurihara H: Vascular abnormalities and elevated blood pressure in mice lacking adrenomedullin gene. Circulation 2001, 104:1964-1971.
40. Hayashi KG, Hosoe M, Sakumoto R, Takahashi T: Temporo-spatial expression of adrenomedullin and its receptors in the bovine placenta. Reprod Biol Endocrinol 2013, 11:62. 10.1186/1477-7827-1111-1162.
41. Shimosawa T, Shibagaki Y, Ishibashi K, Kitamura K, Kangawa K, Kato S, Ando K, Fujita T: Adrenomedullin, an endogenous peptide, counteracts cardiovascular damage. Circulation 2002, 105:106-111.
42. Garayoa M, Bodegas E, Cuttitta F, Montuenga LM: Adrenomedullin in mammalian embryogenesis. Microsc Res Tech 2002, 57:40-54.
43. Lenhart PM, Caron KM: Adrenomedullin and pregnancy: perspectives from animal models to humans. Trends Endocrinol Metab 2012, 23:524-532. doi:510.1016/j.tem.2012.1002.1007. Epub 2012 Mar 1016.
44. Dackor RT, Fritz-Six K, Dunworth WP, Gibbons CL, Smithies O, Caron KM: Hydrops fetalis, cardiovascular defects, and embryonic lethality in mice lacking the calcitonin receptor-like receptor gene. Mol Cell Biol 2006, 26:2511-2518.
45. Ichikawa-Shindo Y, Sakurai T, Kamiyoshi A, Kawate H, Iinuma N, Yoshizawa T, Koyama T, Fukuchi J, Iimuro S, Moriyama N, Kawakami H, Murata T, Kangawa K, Nagai R, Shindo T: The GPCR modulator protein RAMP2 is essential for angiogenesis and vascular integrity. J Clin Invest 2008, 118:29-39.
46. Koyama T, Ochoa-Callejero L, Sakurai T, Kamiyoshi A, Ichikawa-Shindo Y, Iinuma N, Arai T, Yoshizawa T, Iesato Y, Lei Y, Uetake R, Okimura A, Yamauchi A, Tanaka M, Igarashi K, Toriyama Y, Kawate H, Adams RH, Kawakami H, Mochizuki N, Martinez A, Shindo T: Vascular endothelial adrenomedullin-RAMP2 system is essential for vascular integrity and organ homeostasis. Circulation 2013, 127:842-853.
47. Dackor R, Fritz-Six K, Smithies O, Caron K: Receptor activity-modifying proteins 2 and 3 have distinct physiological functions from embryogenesis to old age. J Biol Chem 2007, 282:18094-18099.
48. Plück A: Conditional mutagenesis in mice: the Cre/loxP recombination system. Int J Exp Pathol 1996, 77:269-278.
49. Julian M, Cacho M, Garcia MA, Martin-Santamaria S, de Pascual-Teresa B, Ramos A, Martinez A, Cuttitta F: Adrenomedullin: a new target for the design of small molecule modulators with promising pharmacological activities. Eur J Med Chem 2005, 40:737-750.
50. Chen S, Lu X, Zhao Q, Wang L, Li H, Huang J: Association of adrenomedullin gene polymorphisms and blood pressure in a Chinese population. Hypertens Res 2013, 36:74-78.
51. Hasbak P, Sheykhzade M, Schifter S, Edvinsson L: Potentiated adrenomedullin induced vasorelaxation during hypoxia in organ cultured porcine coronary arteries. J Cardiovasc Pharmacol 2014, 63:58-67.
52. Kono T, Kaneko A, Omiya Y, Ohbuchi K, Ohno N, Yamamoto M: Epithelial transient receptor potential ankyrin 1 (TRPA1)-dependent adrenomedullin upregulates blood flow in rat small intestine. Am J Physiol-Gastrointest Liver Physiol 2013, 304:G428-G436.
53. Kaafarani I, Fernandez-Sauze S, Berenguer C, Chinot O, Delfino C, Dussert C, Metellus P, Boudouresque F, Mabrouk K, Grisoli F, Figarella-Branger D, Martin PM, Ouafik L: Targeting adrenomedullin receptors with systemic delivery of neutralizing antibodies inhibits tumor angiogenesis and suppresses growth of human tumor xenografts in mice. FASEB J 2009, 23:3424-3435.
54. Nicholls MG: Hemodynamic and hormonal actions of adrenomedullin. Braz J Med Biol Res 2004, 37:1247-1253.
55. Nishikimi T, Kuwahara K, Nakagawa Y, Kangawa K, Nakao K: Adrenomedullin in cardiovascular disease: a useful biomarker, its pathological roles and therapeutic application. Curr Protein Pept Sci 2013, 14:256-267.
56. Cam Etoz B, Isbil Buyukcoskun N, Ozluk K: Cardiovascular effects of the intracerebroventricular injection of adrenomedullin: roles of the peripheral vasopressin and central cholinergic systems. Braz J Med Biol Res 2012, 45:250-255. Epub 2012 Mar 2011.
57. Kataoka Y, Miyazaki S, Yasuda S, Nagaya N, Noguchi T, Yamada N, Morii I, Kawamura A, Doi K, Miyatake K, Tomoike H, Kangawa K: The first clinical pilot study of intravenous adrenomedullin administration in patients with acute myocardial infarction. J Cardiovasc Pharmacol 2010, 56:413-419.
58. Martinez A: A new family of angiogenic factors. Cancer Lett 2006, 236:157-163.
59. Garcia-Honduvilla N, Cifuentes A, Manuel Bellon J, Bujan J, Martinez A: The angiogenesis promoter, proadrenomedullin N-terminal 20 peptide (PAMP), improves healing in both normoxic and ischemic wounds either alone or in combination with autologous stem/progenitor cells. Histol Histopathol 2013, 28:115-125.
60. Garcia-Honduvilla N, Cifuentes A, Bellon JM, Bujan J, Martinez A: The angiogenesis promoter, proadrenomedullin N-terminal 20 peptide (PAMP), improves healing in both normoxic and ischemic wounds either alone or in combination with autologous stem/progenitor cells. Histol Histopathol 2013, 28:115-125.
61. Harada K, Yamahara K, Ohnishi S, Otani K, Kanoh H, Ishibashi-Ueda H, Minamino N, Kangawa K, Nagaya N, Ikeda T: Sustained-release adrenomedullin ointment accelerates wound healing of pressure ulcers. Regul Pept 2011, 168:21-26.
62. Hayakawa H, Hirata Y, Kakoki M, Suzuki Y, Nishimatsu H, Nagata D, Suzuki E, Kikuchi K, Nagano T, Kangawa K, Matsuo H, Sugimoto T, Omata M: Role of nitric oxide-cGMP pathway in adrenomedullin-induced vasodilation in the rat. Hypertension 1999, 33:689-693.
63. Wangensteen R, Quesada A, Sainz J, Duarte J, Vargas F, Osuna A: Role of endothelium-derived relaxing factors in adrenomedullin-induced vasodilation in the rat kidney. Eur J Pharmacol 2002, 444:97-102.
64. Yang BC, Lippton H, Gumusel B, Hyman A, Mehta JL: Adrenomedullin dilates rat pulmonary artery rings during hypoxia: role of nitric oxide and vasodilator prostaglandins. J Cardiovasc Pharmacol 1996, 28:458-462.
65. Jougasaki M, Wei CM, Aarhus LL, Heublein DM, Sandberg SM, Burnett JC: Renal localization and actions of adrenomedullin: a natriuretic peptide. Am J Physiol 1995, 268:F657-F663.
66. Samson WK: Adrenomedullin and the control of fluid and electrolyte homeostasis. Annu Rev Physiol 1999, 61:363-389.
67. Nishikimi T: Adrenomedullin in the kidney-renal physiological and pathophysiological roles. Curr Med Chem 2007, 14:1689-1699.
68. Zudaire E, Cuttitta F, Martínez A: Regulation of pancreatic physiology by adrenomedullin and its binding protein. Regul Pept 2003, 112:121-130.
69. Hayashi M, Tojo A, Shimosawa T, Fujita T: The role of adrenomedullin in the renal NADPH oxidase and (pro)renin in diabetic mice. J Diabetes Res 2013, 2013:134395.
70. Marutsuka K, Hatakeyama K, Sato Y, Yamashita A, Sumiyoshi A, Asada Y: Immunohistological localization and possible functions of adrenomedullin. Hypertens Res 2003, 26(Suppl):S33-S40.
71. Rossowski WJ, Cheng BL, Jiang NY, Coy DH: Examination of somatostatin involvement in the inhibitory action of GIP, GLP-1, amylin and adrenomedullin on gastric acid release using a new SRIF antagonist analogue. Br J Pharmacol 1998, 125:1081-1087.
72. Serrano J, Alonso D, Fernandez AP, Encinas JM, Lopez JC, Castro-Blanco S, Fernandez-Vizarra P, Richart A, Santacana M, Uttenthal LO, Bentura ML, Martinez-Murillo R, Martinez A, Cuttitta F, Rodrigo J: Adrenomedullin in the central nervous system. Microsc Res Tech 2002, 57:76-90.
73. Kis B, Abrahám CS, Deli MA, Kobayashi H, Niwa M, Yamashita H, Busija DW, Ueta Y: Adrenomedullin, an autocrine mediator of blood-brain barrier function. Hypertens Res 2003, 26(Suppl):S61-S70.
74. Saita M, Shimokawa A, Kunitake T, Kato K, Hanamori T, Kitamura K, Eto T, Kannan H: Central actions of adrenomedullin on cardiovascular parameters and sympathetic outflow in conscious rats. Am J Physiol 1998, 274:R979-R984.
75. Miyashita K, Itoh H, Arai H, Suganami T, Sawada N, Fukunaga Y, Sone M, Yamahara K, Yurugi-Kobayashi T, Park K, Oyamada N, Taura D, Tsujimoto H, Chao TH, Tamura N, Mukoyama M, Nakao K: The neuroprotective and vasculo-neuro-regenerative roles of adrenomedullin in ischemic brain and its therapeutic potential. Endocrinology 2006, 147:1642-1653.
76. Fernandez AP, Serrano J, Tessarollo L, Cuttitta F, Martinez A: Lack of adrenomedullin in the mouse brain results in behavioral changes, anxiety, and lower survival under stress conditions. Proc Natl Acad Sci U S A 2008, 105:12581-12586.
77. Fernandez AP, Serrano J, Martinez-Murillo R, Martinez A: Lack of adrenomedullin in the central nervous system results in apparently paradoxical alterations on pain sensitivity. Endocrinology 2010, 151:4908-4915.
78. Martinez A, Elsasser TH, Muro-Cacho C, Moody TW, Miller MJ, Macri CJ, Cuttitta F: Expression of adrenomedullin and its receptor in normal and malignant human skin: a potential pluripotent role in the integument. Endocrinology 1997, 138:5597-5604.
79. Nishikimi T, Yoshihara F, Mori Y, Kangawa K, Matsuoka H: Cardioprotective effect of adrenomedullin in heart failure. Hypertens Res 2003, 26(Suppl):S121-S127.
80. Kobayashi K, Kitamura K, Hirayama N, Date H, Kashiwagi T, Ikushima I, Hanada Y, Nagatomo Y, Takenaga M, Ishikawa T, Imamura T, Koiwaya Y, Eto T: Increased plasma adrenomedullin in acute myocardial infarction. Am Heart J 1996, 131:676-680.
81. Wong HK, Cheung TT, Cheung BM: Adrenomedullin and cardiovascular diseases. JRSM Cardiovasc Dis 2012, 1(5).
82. Iqbal N, Alim KS, Aramin H, Iqbal F, Green E, Higginbotham E, Maisel AS: Novel biomarkers for heart failure. Expert Rev Cardiovasc Ther 2013, 11:1155-1169.
83. Nishimatsu H, Hirata Y, Shindo T, Kurihara H, Kakoki M, Nagata D, Hayakawa H, Satonaka H, Sata M, Tojo A, Suzuki E, Kangawa K, Matsuo H, Kitamura T, Nagai R: Role of endogenous adrenomedullin in the regulation of vascular tone and ischemic renal injury: studies on transgenic/knockout mice of adrenomedullin gene. Circ Res 2002, 90:657-663.
84. Nakayama M, Takahashi K, Murakami O, Murakami H, Sasano H, Shirato K, Shibahara S: Adrenomedullin in monocytes and macrophages: possible involvement of macrophage-derived adrenomedullin in atherogenesis. Clin Sci (Lond) 1999, 97:247-251.
85. Shinomiya K, Ohmori K, Ohyama H, Hosomi N, Takahashi T, Osaka K, Kohno M: Association of plasma adrenomedullin with carotid atherosclerosis in chronic ischemic stroke. Peptides 2001, 22:1873-1880.
86. Kohno M, Hanehira T, Kano H, Horio T, Yokokawa K, Ikeda M, Minami M, Yasunari K, Yoshikawa J: Plasma adrenomedullin concentrations in essential hypertension. Hypertension 1996, 27:102-107.
87. Kato J, Kitamura K, Matsui E, Tanaka M, Ishizaka Y, Kita T, Kangawa K, Eto T: Plasma adrenomedullin and natriuretic peptides in patients with essential or malignant hypertension. Hypertens Res 1999, 22:61-65.
88. Kinoshita H, Fujimoto S, Kitamura K, Matsuura Y, Uezono S, Hisanaga S, Eto T: Increased plasma levels of mature adrenomedullin in chronic glomerulonephritis. Nephron 2000, 86:333-338.
89. Hirose T, Totsune K, Mori N, Mori T, Morimoto R, Metoki H, Asayama K, Kikuya M, Ohkubo T, Kohzuki M, Takahashi K, Imai Y: Expression of adrenomedullin 2/intermedin, a possible reno-protective peptide, is decreased in the kidneys of rats with hypertension or renal failure. Am J Physiol Renal Physiol 2010, 299:F128-F134.
90. Chen YX, Li CS: Prognostic value of adrenomedullin in septic patients in the ED. Am J Emerg Med 2013, 31:1017-1021.
91. Chen YX, Li CS: The predictive value of adrenomedullin for development of severe sepsis and septic shock in emergency department. Biomed Res Int 2013, 2013:960101.
92. Oncel MY, Erdeve O, Uras N, Dilmen U: Is pro-adrenomedullin a more useful marker in hospitalized infants with sepsis? Eur J Pediatr 2014, 173:127-128.
93. Pang L, Qi J, Gao Y, Jin H, Du J: Adrenomedullin alleviates pulmonary artery collagen accumulation in rats with pulmonary hypertension induced by high blood flow. Peptides 2014, 54:101-107.
94. Fukuda K, Tsukada H, Oya M, Onomura M, Kodama M, Nakamura H, Hosokawa M, Seino Y: Adrenomedullin promotes epithelial restitution of rat and human gastric mucosa in vitro. Peptides 1999, 20:127-132.
95. Ashizuka S, Kita T, Inatsu H, Kitamura K: Adrenomedullin: a novel therapy for intractable ulcerative colitis. Inflamm Bowel Dis 2013, 19:E26-E27.
96. Ashizuka S, Inatsu H, Kita T, Kitamura K: The first clinical pilot study of adrenomedullin therapy in refractory ulcerative colitis: the initial Six cases. Gastroenterology 2012, 142:S353-S353.
97. Rulle S, Ah Kioon MD, Asensio C, Mussard J, Ea HK, Boissier MC, Liote F, Falgarone G: Adrenomedullin, a neuropeptide with immunoregulatory properties induces semi-mature tolerogenic dendritic cells. Immunology 2012, 136:252-264. doi:210.1111/j.1365-2567.2012.03577.x.
98. Talero E, Di Paola R, Mazzon E, Esposito E, Motilva V, Cuzzocrea S: Anti-inflammatory effects of adrenomedullin on acute lung injury induced by Carrageenan in mice. Mediators Inflamm 2012, 2012:717851. doi:10.1155/2012/717851. Epub 712012 May 717820.
99. Ashizuka S, Ishikawa N, Kato J, Yamaga J, Inatsu H, Eto T, Kitamura K: Effect of adrenomedullin administration on acetic acid-induced colitis in rats. Peptides 2005, 26:2610-2615. Epub 2005 Jun 2623.
100. Ashizuka S, Inagaki Ohara K, Kuwasako K, Kato J, Inatsu H, Kitamura K: Adrenomedullin treatment reduces intestinal inflammation and maintains epithelial barrier function in mice administered dextran sulphate sodium. Microbiol Immunol 2009, 53:573-581. doi:510.1111/j.1348-0421.2009.00159.x.
101. Talero E, Sanchez Fidalgo S, De La Lastra CA, Illanes M, Calvo JR, Motilva V: Acute and chronic responses associated with adrenomedullin administration in experimental colitis. Peptides 2008, 29:2001-2012. doi:2010.1016/j.peptides.2008.2007.2013. Epub 2008 Jul 2029.
102. García-Unzueta MT, Montalbán C, Pesquera C, Berrazueta JR, Amado JA: Plasma adrenomedullin levels in type 1 diabetes. Relationship with clinical parameters. Diabetes Care 1998, 21:999-1003.
103. Lim SC, Morgenthaler NG, Subramaniam T, Wu YS, Goh SK, Sum CF: The relationship between adrenomedullin, metabolic factors, and vascular function in individuals with type 2 diabetes. Diabetes Care 2007, 30:1513-1519.
104. Martínez A, Elsasser TH, Bhathena SJ, Pío R, Buchanan TA, Macri CJ, Cuttitta F: Is adrenomedullin a causal agent in some cases of type 2 diabetes? Peptides 1999, 20:1471-1478.
105. Sah RP, Nagpal SJ, Mukhopadhyay D, Chari ST: New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol 2013, 10:423-433.
106. Lu Y, Xu Y, Tang C: Changes in adrenomedullin in patients with proliferative diabetic retinopathy. Curr Eye Res 2011, 36:1047-1052.
107. Udono-Fujimori R, Udono T, Totsune K, Tamai M, Shibahara S, Takahashi K: Adrenomedullin in the eye. Regul Pept 2003, 112:95-101.
108. Pavel ME, Hoppe S, Papadopoulos T, Linder V, Mohr B, Hahn EG, Lohmann T, Schuppan D: Adrenomedullin is a novel marker of tumor progression in neuroendocrine carcinomas. Horm Metab Res 2006, 38:112-118.
109. Dai X, Ma W, He XJ, Jha RK: Elevated expression of adrenomedullin is correlated with prognosis and disease severity in osteosarcoma. Med Oncol 2013, 30:347.
110. Aggarwal G, Ramachandran V, Javeed N, Arumugam T, Dutta S, Klee GG, Klee EW, Smyrk TC, Bamlet W, Han JJ, Rumie Vittar NB, de Andrade M, Mukhopadhyay D, Petersen GM, Fernandez-Zapico ME, Logsdon CD, Chari ST: Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in beta cells and mice. Gastroenterology 2012, 143:1510-1517. e1511.
111. Letizia C, Tamburrano G, Alo P, Paoloni A, Caliumi C, Marinoni E, Di Iorio R, D'Erasmo E: Adrenomedullin, a new peptide, in patients with insulinoma. Eur J Endocrinol 2001, 144:517-520.
112. Letizia C, Di Iorio R, De Toma G, Marinoni E, Cerci S, Celi M, Subioli S, D'Erasmo E: Circulating adrenomedullin is increased in patients with corticotropin-dependent Cushing's syndrome due to pituitary adenoma. Metabolism 2000, 49:760-763.
113. Letizia C, De Toma G, Cerci S, Massa R, Coassin S, Subioli S, Scuro L, De Ciocchis A: Adrenomedullin levels are high in primary aldosteronism due to adenoma and decline after surgical cure. Blood Press 1998, 7:19-23.
114. Letizia C, De Toma G, Caliumi C, Cerci S, Massa R, Loria RD, Alo P, Marinoni EM, Diacinti D, D'Erasmo E: Plasma adrenomedullin concentrations in patients with adrenal pheochromocytoma. Horm Metab Res 2001, 33:290-294.
115. Hummel TR, Jessen WJ, Miller SJ, Kluwe L, Mautner VF, Wallace MR, Lazaro C, Page GP, Worley PF, Aronow BJ, Schorry EK, Ratner N: Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin. Clin Cancer Res 2010, 16:5048-5057.
116. Keleg S, Kayed H, Jiang X, Penzel R, Giese T, Buchler MW, Friess H, Kleeff J: Adrenomedullin is induced by hypoxia and enhances pancreatic cancer cell invasion. Int J Cancer 2007, 121:21-32.
117. Cotesta D, Caliumi C, Alo P, Petramala L, Reale MG, Masciangelo R, Signore A, Cianci R, D'Erasmo E, Letizia C: High plasma levels of human chromogranin A and adrenomedullin in patients with pheochromocytoma. Tumori 2005, 91:53-58.
118. Michelsen J, Thiesson H, Walter S, Ottosen PD, Skott O, Jensen BL: Tissue expression and plasma levels of adrenomedullin in renal cancer patients. Clin Sci (Lond) 2006, 111:61-70.
119. Nouguerede E, Berenguer C, Garcia S, Bennani B, Delfino C, Nanni I, Dahan L, Gasmi M, Seitz JF, Martin PM, Ouafik L: Expression of adrenomedullin in human colorectal tumors and its role in cell growth and invasion in vitro and in xenograft growth in vivo. Cancer Med 2013, 2:196-207.
120. Liu AG, Zhang XZ, Li FB, Zhao YL, Guo YC, Yang RM: RNA interference targeting adrenomedullin induces apoptosis and reduces the growth of human bladder urothelial cell carcinoma. Med Oncol 2013, 30:616.
121. Deville JL, Bartoli C, Berenguer C, Fernandez-Sauze S, Kaafarani I, Delfino C, Fina F, Salas S, Muracciole X, Mancini J, Lechevallier E, Martin PM, Figarella-Branger D, Ouafik L, Daniel L: Expression and role of adrenomedullin in renal tumors and value of its mRNA levels as prognostic factor in clear-cell renal carcinoma. Int J Cancer 2009, 125:2307-2315.
122. Logsdon CD, Simeone DM, Binkley C, Arumugam T, Greenson JK, Giordano TJ, Misek DE, Kuick R, Hanash S: Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res 2003, 63:2649-2657.
123. Deng B, Zhang S, Miao Y, Han Z, Zhang X, Wen F, Zhang Y: Adrenomedullin expression in epithelial ovarian cancers and promotes HO8910 cell migration associated with upregulating integrin alpha5beta1 and phosphorylating FAK and paxillin. J Exp Clin Cancer Res 2012, 31:19.
124. Hata K, Takebayashi Y, Akiba S, Fujiwaki R, Iida K, Nakayama K, Nakayama S, Fukumoto M, Miyazaki K: Expression of the adrenomedullin gene in epithelial ovarian cancer. Mol Hum Reprod 2000, 6:867-872.
125. Evans JJ, Chitcholtan K, Dann JM, Guilford P, Harris G, Lewis LK, Nagase J, Welkamp AA, Zwerus R, Sykes PH: Adrenomedullin interacts with VEGF in endometrial cancer and has varied modulation in tumours of different grades. Gynecol Oncol 2012, 125:214-219.
126. Hague S, Zhang L, Oehler MK, Manek S, MacKenzie IZ, Bicknell R, Rees MC: Expression of the hypoxically regulated angiogenic factor adrenomedullin correlates with uterine leiomyoma vascular density. Clin Cancer Res 2000, 6:2808-2814.
127. Carlson MR, Pope WB, Horvath S, Braunstein JG, Nghiemphu P, Tso CL, Mellinghoff I, Lai A, Liau LM, Mischel PS, Dong J, Nelson SF, Cloughesy TF: Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2. Clin Cancer Res 2007, 13:2592-2598.
128. Ouafik L, Sauze S, Boudouresque F, Chinot O, Delfino C, Fina F, Vuaroqueaux V, Dussert C, Palmari J, Dufour H, Grisoli F, Casellas P, Brunner N, Martin PM: Neutralization of adrenomedullin inhibits the growth of human glioblastoma cell lines in vitro and suppresses tumor xenograft growth in vivo. Am J Pathol 2002, 160:1279-1292.
129. Satoh F, Takahashi K, Murakami O, Totsune K, Sone M, Ohneda M, Abe K, Miura Y, Hayashi Y, Sasano H: Adrenomedullin in human brain, adrenal glands and tumor tissues of pheochromocytoma, ganglioneuroblastoma and neuroblastoma. J Clin Endocrinol Metab 1995, 80:1750-1752.
130. Murakami O, Takahashi K, Satoh F, Totsune K, Sone M, Arihara Z, Andoh N, Mouri T: Expression of adrenomedullin and adrenomedullin mRNA in ectopic ACTH-secreting tumors. Eur J Endocrinol 1998, 138:436-439.
131. Knerr I, Schuster S, Nomikos P, Buchfelder M, Dotsch J, Schoof E, Fahlbusch R, Rascher W: Gene expression of adrenomedullin, leptin, their receptors and neuropeptide Y in hormone-secreting and non-functioning pituitary adenomas, meningiomas and malignant intracranial tumours in humans. Neuropathol Appl Neurobiol 2001, 27:215-222.
132. Park SC, Yoon JH, Lee JH, Yu SJ, Myung SJ, Kim W, Gwak GY, Lee SH, Lee SM, Jang JJ, Suh KS, Lee HS: Hypoxia-inducible adrenomedullin accelerates hepatocellular carcinoma cell growth. Cancer Lett 2008, 271:314-322.
133. Nakata T, Seki N, Miwa S, Kobayashi A, Soeda J, Nimura Y, Kawasaki S, Miyagawa S: Identification of genes associated with multiple nodules in hepatocellular carcinoma using cDNA microarray: multicentric occurrence or intrahepatic metastasis? Hepatogastroenterol 2008, 55:865-872.
134. Martinez A, Miller MJ, Unsworth EJ, Siegfried JM, Cuttitta F: Expression of adrenomedullin in normal human lung and in pulmonary tumors. Endocrinology 1995, 136:4099-4105.
135. Liu J, Kahri AI, Heikkila P, Voutilainen R: Adrenomedullin gene expression and its different regulation in human adrenocortical and medullary tumors. J Endocrinol 1997, 155:483-490.
136. Takahashi K, Satoh F, Sone M, Totsune K, Arihara Z, Noshiro T, Mouri T, Murakami O: Expression of adrenomedullin mRNA in adrenocortical tumors and secretion of adrenomedullin by cultured adrenocortical carcinoma cells. Peptides 1998, 19:1719-1724.
137. Satoh F, Takahashi K, Murakami O, Totsune K, Sone M, Ohneda M, Abe K, Miura Y, Mouri T: Immunoreactive adrenomedullin in human adrenal glands and adrenal tumors. Cancer Detect Prev 1997, 21:51-54.
138. Zudaire E, Martinez A, Garayoa M, Pio R, Kaur G, Woolhiser MR, Metcalfe DD, Hook WA, Siraganian RP, Guise TA, Chirgwin JM, Cuttitta F: Adrenomedullin is a cross-talk molecule that regulates tumor and mast cell function during human carcinogenesis. Am J Pathol 2006, 168:280-291.
139. Udono T, Totsune K, Takahashi K, Abe T, Sato M, Shibahara S, Tamai M: Increased expression of adrenomedullin mRNA in the tissues of intraocular and orbital tumors. Am J Ophthalmol 2000, 129:555-556.
140. Chen P, Huang Y, Bong R, Ding Y, Song N, Wang X, Song X, Luo Y: Tumor-associated macrophages promote angiogenesis and melanoma growth via adrenomedullin in a paracrine and autocrine manner. Clin Cancer Res 2011, 17:7230-7239.
141. Buyukberber S, Sari I, Camci C, Buyukberber NM, Sevinc A, Turk HM: Adrenomedullin expression does not correlate with survival in lung cancer. Med Oncol 2007, 24:245-249.
142. Liu J, Butzow R, Hyden-Granskog C, Voutilainen R: Expression of adrenomedullin in human ovaries, ovarian sex cord-stromal tumors and cultured granulosa-luteal cells. Gynecol Endocrinol 2009, 25:96-103.
143. Dotsch J, Harmjanz A, Christiansen H, Hanze J, Lampert F, Rascher W: Gene expression of neuronal nitric oxide synthase and adrenomedullin in human neuroblastoma using real-time PCR. Int J Cancer 2000, 88:172-175.
144. Oehler MK, Fischer DC, Orlowska-Volk M, Herrle F, Kieback DG, Rees MC, Bicknell R: Tissue and plasma expression of the angiogenic peptide adrenomedullin in breast cancer. Br J Cancer 2003, 89:1927-1933.
145. Lombardero M, Kovacs K, Horvath E, Scheithauer BW, Rotondo F, Salehi F, Lloyd RV: Adrenomedullin expression in pituitary adenomas and nontumoral adenohypophyses. Histol Histopathol 2008, 23:11-17.
146. Sion-Vardy N, Tzikinovsky A, Bolotyn A, Segal S, Fishman D: Augmented expression of chromogranin A and serotonin in peri-malignant benign prostate epithelium as compared to adenocarcinoma. Pathol Res Pract 2004, 200:493-499.
147. Uemura M, Yamamoto H, Takemasa I, Mimori K, Mizushima T, Ikeda M, Sekimoto M, Doki Y, Mori M: Hypoxia-inducible adrenomedullin in colorectal cancer. Anticancer Res 2011, 31:507-514.
148. Wang L, Gala M, Yamamoto M, Pino MS, Kikuchi H, Shue DS, Shirasawa S, Austin TR, Lynch MP, Rueda BR, Zukerberg LR, Chung DC: Adrenomedullin is a therapeutic target in colorectal cancer. Int J Cancer 2014, 134:2041-2050.
149. Baranello C, Mariani M, Andreoli M, Fanelli M, Martinelli E, Ferrandina G, Scambia G, Shahabi S, Ferlini C: Adrenomedullin in ovarian cancer: foe in vitro and friend in vivo? PLoS One 2012, 7:e40678.
150. Michishita M, Minegishi T, Abe K, Kangawa K, Kojima M, Ibuki Y: Expression of adrenomedullin in the endometrium of the human uterus. Obstet Gynecol 1999, 93:66-70.
151. Ramachandran V, Arumugam T, Hwang RF, Greenson JK, Simeone DM, Logsdon CD: Adrenomedullin is expressed in pancreatic cancer and stimulates cell proliferation and invasion in an autocrine manner via the adrenomedullin receptor, ADMR. Cancer Res 2007, 67:2666-2675.
152. Thouennon E, Pierre A, Tanguy Y, Guillemot J, Manecka DL, Guerin M, Ouafik L, Muresan M, Klein M, Bertherat J, Lefebvre H, Plouin PF, Yon L, Anouar Y: Expression of trophic amidated peptides and their receptors in benign and malignant pheochromocytomas: high expression of adrenomedullin RDC1 receptor and implication in tumoral cell survival. Endocr Relat Cancer 2010, 17:637-651.
153. Rocchi P, Boudouresque F, Zamora AJ, Muracciole X, Lechevallier E, Martin PM, Ouafik L: Expression of adrenomedullin and peptide amidation activity in human prostate cancer and in human prostate cancer cell lines. Cancer Res 2001, 61:1196-1206.
154. Cheung BM, Ong KL, Tso AW, Leung RY, Cherny SS, Sham PC, Lam TH, Lam KS: Plasma adrenomedullin level is related to a single nucleotide polymorphism in the adrenomedullin gene. Eur J Endocrinol 2011, 165:571-577.
155. Martinez-Herrero S, Martinez A: Cancer protection elicited by a single nucleotide polymorphism close to the adrenomedullin gene. J Clin Endocrinol Metab 2013, 98:E807-E810.
156. Belting M, Almgren P, Manjer J, Hedblad B, Struck J, Wang TJ, Bergmann A, Melander O: Vasoactive peptides with angiogenesis-regulating activity predict cancer risk in males. Cancer Epidemiol Biomarkers Prev 2012, 21:513-522.
157. Avraamides CJ, Garmy-Susini B, Varner JA: Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 2008, 8:604-617.
158. Cairns RA, Harris IS, Mak TW: Regulation of cancer cell metabolism. Nat Rev Cancer 2011, 11:85-95.
159. Wouters BG, Koritzinsky M: Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 2008, 8:851-864.
160. Portal-Nunez S, Shankavaram UT, Rao M, Datrice N, Atay S, Aparicio M, Camphausen KA, Fernandez-Salguero PM, Chang H, Lin P, Schrump DS, Garantziotis S, Cuttitta F, Zudaire E: Aryl hydrocarbon receptor-induced adrenomedullin mediates cigarette smoke carcinogenicity in humans and mice. Cancer Res 2012, 72:5790-5800.
161. Albertin G, Forneris M, Aragona F, Nussdorfer GG: Expression of adrenomedullin and its receptors in the human adrenal cortex and aldosteronomas. Int J Mol Med 2001, 8:423-426.
162. Berenguer C, Boudouresque F, Dussert C, Daniel L, Muracciole X, Grino M, Rossi D, Mabrouk K, Figarella-Branger D, Martin PM, Ouafik L: Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells. Oncogene 2008, 27:506-518.
163. Forneris M, Gottardo L, Albertin G, Malendowicz LK, Nussdorfer GG: Expression and function of adrenomedullin and its receptors in Conn's adenoma cells. Int J Mol Med 2001, 8:675-679.
164. Martinez A: Biology of adrenomedullin. Introduction. Microsc Res Tech 2002, 57:1-2.
165. Martinez A, Vos M, Guedez L, Kaur G, Chen Z, Garayoa M, Pio R, Moody T, Stetler-Stevenson WG, Kleinman HK, Cuttitta F: The effects of adrenomedullin overexpression in breast tumor cells. J Natl Cancer Inst 2002, 94:1226-1237.
166. Miller MJ, Martinez A, Unsworth EJ, Thiele CJ, Moody TW, Elsasser T, Cuttitta F: Adrenomedullin expression in human tumor cell lines. Its potential role as an autocrine growth factor. J Biol Chem 1996, 271:23345-23351.
167. Nikitenko LL, Fox SB, Kehoe S, Rees MC, Bicknell R: Adrenomedullin and tumour angiogenesis. Br J Cancer 2006, 94:1-7.
168. Nikitenko LL, MacKenzie IZ, Rees MC, Bicknell R: Adrenomedullin is an autocrine regulator of endothelial growth in human endometrium. Mol Hum Reprod 2000, 6:811-819.
169. Miseki T, Kawakami H, Natsuizaka M, Darmanin S, Cui HY, Chen J, Fu Q, Okada F, Shindo M, Higashino F, Asaka M, Hamuro J, Kobayashi M: Suppression of tumor growth by intra-muscular transfer of naked DNA encoding adrenomedullin antagonist. Cancer Gene Ther 2007, 14:39-44.
170. Benes L, Kappus C, McGregor GP, Bertalanffy H, Mennel HD, Hagner S: The immunohistochemical expression of calcitonin receptor-like receptor (CRLR) in human gliomas. J Clin Pathol 2004, 57:172-176.
171. Metellus P, Voutsinos-Porche B, Nanni-Metellus I, Colin C, Fina F, Berenguer C, Dussault N, Boudouresque F, Loundou A, Intagliata D, Chinot O, Martin PM, Figarella-Branger D, Ouafik L: Adrenomedullin expression and regulation in human glioblastoma, cultured human glioblastoma cell lines and pilocytic astrocytoma. Eur J Cancer 2011, 47:1727-1735.
172. Abasolo I, Montuenga LM, Calvo A: Adrenomedullin prevents apoptosis in prostate cancer cells. Regul Pept 2006, 133:115-122.
173. Abasolo I, Wang Z, Montuenga LM, Calvo A: Adrenomedullin inhibits prostate cancer cell proliferation through a cAMP-independent autocrine mechanism. Biochem Biophys Res Commun 2004, 322:878-886.
174. Berenguer-Daize C, Boudouresque F, Bastide C, Tounsi A, Benyahia Z, Acunzo J, Dussault N, Delfino C, Baeza N, Daniel L, Cayol M, Rossi D, El Battari A, Bertin D, Mabrouk K, Martin PM, Ouafik L: Adrenomedullin blockade suppresses growth of human hormone-independent prostate tumor xenograft in mice. Clin Cancer Res 2013, 19:6138-6150.
175. Joshi BH, Leland P, Calvo A, Green JE, Puri RK: Human adrenomedullin up-regulates interleukin-13 receptor alpha2 chain in prostate cancer in vitro and in vivo: a novel approach to sensitize prostate cancer to anticancer therapy. Cancer Res 2008, 68:9311-9317.
176. Chen P, Pang X, Zhang Y, He Y: Effect of inhibition of the adrenomedullin gene on the growth and chemosensitivity of ovarian cancer cells. Oncol Rep 2012, 27:1461-1466.
177. Zhang Y, Zhang S, Shang H, Pang X, Zhao Y: Basic fibroblast growth factor upregulates adrenomedullin expression in ovarian epithelial carcinoma cells via JNK-AP-1 pathway. Regul Pept 2009, 157:44-50.
178. Giacalone PL, Vuaroqueaux V, Daures JP, Houafic L, Martin PM, Laffargue F, Maudelonde T: Expression of adrenomedullin in human ovaries, ovarian cysts and cancers. Correlation with estrogens receptor status. Eur J Obstet Gynecol Reprod Biol 2003, 110:224-229.
179. Kocemba KA, van Andel H, de Haan-Kramer A, Mahtouk K, Versteeg R, Kersten MJ, Spaargaren M, Pals ST: The hypoxia target adrenomedullin is aberrantly expressed in multiple myeloma and promotes angiogenesis. Leukemia 2013, 27:1729-1737.
180. Brown JM, Giaccia AJ: The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998, 58:1408-1416.
181. Genbacev O, Zhou Y, Ludlow JW, Fisher SJ: Regulation of human placental development by oxygen tension. Science 1997, 277:1669-1672.
182. Wenger RH, Gassmann M: Oxygen(es) and the hypoxia-inducible factor-1. Biol Chem 1997, 378:609-616.
183. Zudaire E, Martinez A, Cuttitta F: Adrenomedullin and cancer. Regul Pept 2003, 112:175-183.
184. Nakayama M, Takahashi K, Murakami O, Shirato K, Shibahara S: Induction of adrenomedullin by hypoxia and cobalt chloride in human colorectal carcinoma cells. Biochem Biophys Res Commun 1998, 243:514-517.
185. Oehler MK, Hague S, Rees MC, Bicknell R: Adrenomedullin promotes formation of xenografted endometrial tumors by stimulation of autocrine growth and angiogenesis. Oncogene 2002, 21:2815-2821.
186. Brekhman V, Lugassie J, Zaffryar-Eilot S, Sabo E, Kessler O, Smith V, Golding H, Neufeld G: Receptor activity modifying protein-3 mediates the protumorigenic activity of lysyl oxidase-like protein-2. FASEB J 2011, 25:55-65.
187. Ishikawa T, Chen J, Wang J, Okada F, Sugiyama T, Kobayashi T, Shindo M, Higashino F, Katoh H, Asaka M, Kondo T, Hosokawa M, Kobayashi M: Adrenomedullin antagonist suppresses in vivo growth of human pancreatic cancer cells in SCID mice by suppressing angiogenesis. Oncogene 2003, 22:1238-1242.
188. Karpinich NO, Kechele DO, Espenschied ST, Willcockson HH, Fedoriw Y, Caron KM: Adrenomedullin gene dosage correlates with tumor and lymph node lymphangiogenesis. FASEB J 2013, 27:590-600.
189. Tsuchiya K, Hida K, Hida Y, Muraki C, Ohga N, Akino T, Kondo T, Miseki T, Nakagawa K, Shindoh M, Harabayashi T, Shinohara N, Nonomura K, Kobayashi M: Adrenomedullin antagonist suppresses tumor formation in renal cell carcinoma through inhibitory effects on tumor endothelial cells and endothelial progenitor mobilization. Int J Oncol 2010, 36:1379-1386.
190. Caron KM, Smithies O: Extreme hydrops fetalis and cardiovascular abnormalities in mice lacking a functional Adrenomedullin gene. Proc Natl Acad Sci U S A 2001, 98:615-619.
191. Iwase T, Nagaya N, Fujii T, Itoh T, Ishibashi-Ueda H, Yamagishi M, Miyatake K, Matsumoto T, Kitamura S, Kangawa K: Adrenomedullin enhances angiogenic potency of bone marrow transplantation in a rat model of hindlimb ischemia. Circulation 2005, 111:356-362.
192. Martinez A, Julian M, Bregonzio C, Notari L, Moody TW, Cuttitta F: Identification of vasoactive nonpeptidic positive and negative modulators of adrenomedullin using a neutralizing antibody-based screening strategy. Endocrinology 2004, 145:3858-3865.
193. Iimuro S, Shindo T, Moriyama N, Amaki T, Niu P, Takeda N, Iwata H, Zhang Y, Ebihara A, Nagai R: Angiogenic effects of adrenomedullin in ischemia and tumor growth. Circ Res 2004, 95:415-423.
194. Hay DL, Walker CS, Poyner DR: Adrenomedullin and calcitonin gene-related peptide receptors in endocrine-related cancers: opportunities and challenges. Endocr Relat Cancer 2011, 18:C1-C14.
195. Martinez A, Zudaire E, Portal-Nunez S, Guedez L, Libutti SK, Stetler-Stevenson WG, Cuttitta F: Proadrenomedullin NH2-terminal 20 peptide is a potent angiogenic factor, and its inhibition results in reduction of tumor growth. Cancer Res 2004, 64:6489-6494.